These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 20233784

  • 1. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.
    Regan FM, Williams RM, McDonald A, Umpleby AM, Acerini CL, O'Rahilly S, Hovorka R, Semple RK, Dunger DB.
    J Clin Endocrinol Metab; 2010 May; 95(5):2113-22. PubMed ID: 20233784
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P, Flück CE, Mullis PE.
    Horm Res Paediatr; 2010 May; 73(2):140-7. PubMed ID: 20190552
    [Abstract] [Full Text] [Related]

  • 3. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005 May; 6(2):120-7. PubMed ID: 15777106
    [Abstract] [Full Text] [Related]

  • 4. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR, Sleevi M, Allan G, Sommer A.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [Abstract] [Full Text] [Related]

  • 6. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.
    Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smirnow AM, Thornton CA, Moxley RT.
    Arch Neurol; 2011 Jan; 68(1):37-44. PubMed ID: 20837825
    [Abstract] [Full Text] [Related]

  • 7. Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.
    Klevebro S, Hellgren G, Hansen-Pupp I, Wackernagel D, Hallberg B, Borg J, Pivodic A, Smith L, Ley D, Hellström A.
    Growth Horm IGF Res; 2020 Feb; 50():1-8. PubMed ID: 31756675
    [Abstract] [Full Text] [Related]

  • 8. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA, Camacho-Hübner C, Bergman RN, Barter D, Clark AJ, Savage MO.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [Abstract] [Full Text] [Related]

  • 9. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N, Erotokritou-Mulligan I, Bartlett C, Nevitt SP, Francis M, Bassett EE, Cowan DA, Sönksen PH, Holt RI.
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [Abstract] [Full Text] [Related]

  • 10. Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study.
    Hansen-Pupp I, Hellström A, Hamdani M, Tocoian A, Kreher NC, Ley D, Hallberg B.
    Growth Horm IGF Res; 2017 Oct; 36():44-51. PubMed ID: 28934640
    [Abstract] [Full Text] [Related]

  • 11. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
    Williams RM, McDonald A, O'Savage M, Dunger DB.
    Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.
    Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):205-10. PubMed ID: 8027228
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.
    Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR.
    Diabetes; 1996 Jan; 45(1):91-100. PubMed ID: 8522066
    [Abstract] [Full Text] [Related]

  • 14. rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.
    Ley D, Hallberg B, Hansen-Pupp I, Dani C, Ramenghi LA, Marlow N, Beardsall K, Bhatti F, Dunger D, Higginson JD, Mahaveer A, Mezu-Ndubuisi OJ, Reynolds P, Giannantonio C, van Weissenbruch M, Barton N, Tocoian A, Hamdani M, Jochim E, Mangili A, Chung JK, Turner MA, Smith LEH, Hellström A, study team.
    J Pediatr; 2019 Mar; 206():56-65.e8. PubMed ID: 30471715
    [Abstract] [Full Text] [Related]

  • 15. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [Abstract] [Full Text] [Related]

  • 16. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N, Erotokritou-Mulligan I, Nevitt SP, Francis M, Bartlett C, Cowan DA, Bassett EE, Sönksen PH, Holt RI.
    Drug Test Anal; 2013 Sep; 5(11-12):843-9. PubMed ID: 24173773
    [Abstract] [Full Text] [Related]

  • 17. Safety aspects of longitudinal administration of IGF-I/IGFBP-3 complex in neonatal mice.
    Hellgren G, Han W, Wang X, Löfqvist C, Hagberg H, Mallard C, Hellström A.
    Growth Horm IGF Res; 2011 Aug; 21(4):205-11. PubMed ID: 21696987
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.